HEATHER POPHAM: Open Payments
NPI 1093086985 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,094 in 46 payments from 21 companies in 2025. Trend: 2023 $2,577 · 2024 $1,635 · 2025 $1,094
Food & beverage: $1,094
| Company | Payments | Amount |
|---|---|---|
| TG Therapeutics, Inc. | 4 | $140 |
| Neurocrine BioSciences, Inc. | 5 | $130 |
| Novartis Pharmaceuticals Corporation | 4 | $112 |
| UCB, Inc. | 3 | $88 |
| Alkermes, Inc. | 3 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $75 |
| Amneal Pharmaceuticals LLC | 3 | $72 |
| SK Life Science, Inc. | 2 | $56 |
| Neos Therapeutics, LP | 3 | $55 |
| E.R. Squibb & Sons, L.L.C. | 2 | $47 |
Products named: BRIUMVI, INGREZZA, KESIMPTA, ARISTADA, CAPLYTA, CREXONT, Nayzilam, Adzenys XR-ODT.
Industry payments across MO — which companies pay providers there.
